8
Treatment
Table 2. Emetic Risk of Single Oral Antineoplastic Agents
in Adults
a
Risk Level Agent
High
(>90%)
Hexamethylmelamine
Procarbazine
Moderate
(30%–90%)
Bosutinib
Cabozantinib
Ceritinib
Crizotinib
Cyclophosphamide
Imatinib
Lenvatinib
TAS-102 (trifluridine-tipiracil)
Temozolomide
Vinorelbine
Low
(10%–30%)
Afatinib
Alectinib
Axatinib
Capecitabine
Cobimetinib
Dabrafenib
Dasatinib
Everolimus
Etoposide
Fludarabine
Ibrutinib
Idelalisib
Ixazomib
Lapatinib
Lenalidomide
Olaparib
Osimertinib
Nilotinib
Palbociclib
Pazopanib
Ponatinib
Panobinostat
Regorafenib
Sonidegib
Sunitinib
Tegafur-Uracil
alidomide
Trametinib
Vandetanib
Venetoclax
Vorinostat
Minimal
(<10%)
Chlorambucil
Erlotinib
Gefitinib
Hydroxyurea
Melphalan
Methotrexate
Pomalidomide
Ruxolitinib
Sorafenib
6-ioguanine
Vemurafenib
Vismodegib
a
Classified emetic potential of oral agents based on a full course of therapy and not a single dose.
Adapted from Jordan K et al: 2016 Updated MASCC/ESMO consensus recommendations: Emetic
risk classification and evaluation of the emetogenicity of antineoplastic agents. Support Care Cancer
25:271-275, 2017, with permission of Springer.
